budesonide/formoterol hfa inhaler (Symbicort)
Title: budesonide/formoterol hfa inhaler (Symbicort)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 10/20/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 20, 2015 Category: Drugs & Pharmacology Source Type: news
Regular vs As-Needed Budesonide/Formoterol in Stable AsthmaRegular vs As-Needed Budesonide/Formoterol in Stable Asthma
In patients with moderate stable asthma, as-needed budesonide and formoterol therapy is less effective than the regular budesonide and formoterol treatment that's recommended by the 2014 revision of the Global Initiative for Asthma guidelines. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 29, 2014 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
Budesonide - Formoterol Used As Needed Beneficial in Mild Asthma
Superior to terbutaline with respect to asthma control, non - inferior to budesonide for exacerbations (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 11, 2014 Category: Respiratory Medicine Tags: Family Medicine, Internal Medicine, Emergency Medicine, Nursing, Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news
EC's CHMP Recommends Combo Inhalers for COPD, AsthmaEC's CHMP Recommends Combo Inhalers for COPD, Asthma
The committee has endorsed the combination of aclidinium bromide/formoterol fumarate for COPD, and a budesonide/formoterol combination for COPD and asthma. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 26, 2014 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news
Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety...
LifeScienceIndustryResearch.com adds “Symbicort (Asthma) - Forecast and Market Analysis to 2023” to its store. Report provides Sales information covered for the US, France, Germany, Italy, Spain, the...(PRWeb September 20, 2014)Read the full story at http://www.prweb.com/releases/symbicort-asthma-forecast/market-analysis-to-2023/prweb12184403.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 20, 2014 Category: Pharmaceuticals Source Type: news
CHMP Issues Positive Opinion for Teva's DuoResp Spiromax
Teva Pharmaceuticals announced it has received opinion from theEuropean Medicines Agency's(EMA)Committee for Medicinal Products for Human Use(CHMP) for marketing authorization of its treatment DuoResp®Spiromax®(budesonide & formoterol fumarate dihydrate) inhalation powder. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 26, 2014 Category: Pharmaceuticals Source Type: news
Budesonide/Formoterol Therapy in AsthmaBudesonide/Formoterol Therapy in Asthma
Asthma sufferers in Asia and beyond may benefit from this one-two punch combo. Find out why. BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 9, 2013 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
AstraZeneca - Fourth Quarter and Full Year Results 2012
LONDON, Jan. 31, 2013 - Financial performance for the full year
reflects the loss of exclusivity on several brands. At constant
exchange rates (CER), revenue declined by 15 percent and Core EPS
declined by 9 percent
Brilinta/Brilique, Symbicort,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2013 Category: Pharmaceuticals Source Type: news
